Skip to main content

Table 2 Dosimetric data for PTV, uPRV and OAR with and without ERB. Comparison between the treatment plans Vmref and Vm4

From: Urethra-sparing stereotactic body radiotherapy for prostate cancer: how much can the rectal wall dose be reduced with or without an endorectal balloon?

 

ERB

No ERB

 

Vmref

Vm4

P-value

Vmref

Vm4

P-value

PTV

 HI (u.a.)

0.096 [0.071–0.119]

0.099 [0.082–0.121]

0.721

0.086 [0.066–0.102]

0.096 [0.076–0.105]

0.156

 DSC (u.a.)

0.779 [0.714–0.898]

0.773 [0.689–0.906]

1

0.810 [0.738–0.948]

0.795 [0.698–0.89]

1

 D2% (Gy)

38.0 [37–38.9]

38.1 [37.4–39]

0.433

37.6 [36.8–38.2]

38.0 [37.2–38.3]

0.276

uPRV

 HI (u.a.)

0.088 [0.051–0.13]

0.092 [0.06–0.121]

1

0.099 [0.057–0.139]

0.098 [0.063–0.199]

1

Rwall

 D10% (Gy)

32.6 [29.9–35.8]

32.4 [25.6–35.7]

0.229

31.8 [29.9–35.6]

30.9 [26.7–35.3]

0.172

 D20% (Gy)

23.1 [18.2–28.8]

19.8 [10.7–27.6]

<  0.001

24.7 [19.2–29.5]

19.2 [14.4–28.5]

<  0.001

 D30% (Gy)

17.9 [15–22.9]

8.5 [6.2–13.1]

<  0.001

19.6 [14.5–24.9]

8.3 [6.1–13.7]

<  0.001

 D40% (Gy)

15.2 [13–20.8]

6.5 [5.5–7.3]

<  0.001

16.6 [12.5–23.5]

6.0 [5.1–7.3]

<  0.001

 D50% (Gy)

12.9 [4.2–19.6]

6.0 [3.3–6.8]

<  0.001

12.8 [6.3–22.2]

5.0 [4.1–6.5]

<  0.001

 D60% (Gy)

9.1 [2.5–18.2]

5.4 [2.2–6.4]

<  0.001

6.1 [2.4–19.7]

4.1 [2.2–5.8]

0.041

 Dmed (Gy)

12.9 [4.1–19.5]

5.9 [3.3–6.7]

<  0.001

12.2 [6.3–22.1]

4.9 [4–6.5]

<  0.001

Bwall

 V18.1 Gy (%)

32.6 [15.6–47.5]

28.5 [13.3–45.5]

0.010

26.0 [14.9–44.8]

23.2 [13.1–41.8]

0.036

Fheads

 D2%

10.6 [9–14.1]

16.3 [13.7–17.8]

<  0.001

11 [8.3–12.6]

13.3 [10.7–16.5]

0.141

MU

2110 [1788–2478]

2897 [2515–3168]

<  0.001

2256 [1834–2897]

2763 [2419–3161]

0.002